RJFSA
PACB icon

Raymond James Financial Services Advisors’s Pacific Biosciences PACB Stock Holding History

Raymond James Financial Services Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,530
Closed -$19.9K – 3529
2024
Q2 		$19.9K Sell
14,530
-10,830
-43% -$21.9K ﹤0.01% 3346
2024
Q1 		$95.1K Buy
25,360
+4,578
+22% +$26.8K ﹤0.01% 3231
2023
Q4 		$204K Buy
20,782
+8,168
+65% +$66.8K ﹤0.01% 2983
2023
Q3 		$105K Buy
+12,614
New +$144K ﹤0.01% 3054
2021
Q3 		– Sell
-7,556
Closed -$264K – 3383
2021
Q2 		$264K Sell
7,556
-4,947
-40% -$144K ﹤0.01% 2807
2021
Q1 		$416K Buy
+12,503
New +$438K ﹤0.01% 2409

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Raymond James Financial Services Advisors's PACB Position: Q3 2024 in Review

Raymond James Financial Services Advisors sold out of Pacific Biosciences (PACB) in Q3 2024, closing a stake of 14,530 shares — an estimated $19.9K sold.

Raymond James Financial Services Advisors first reported a position in PACB in Q1 2021 and held it in 6 quarters. The position peaked at $416K in Q1 2021. 226 funds tracked by Wall St. Rank hold PACB as of Q3 2024.

  • Raymond James Financial Services Advisors reported no remaining Pacific Biosciences position as of Q3 2024 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 14,530 Pacific Biosciences shares in Q3 2024, an estimated $19.9K.
  • Raymond James Financial Services Advisors first reported a position in Pacific Biosciences in Q1 2021 and held it in 6 quarters.
  • Raymond James Financial Services Advisors's Pacific Biosciences position peaked at $416K in Q1 2021.
  • 226 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.